TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report report published on Monday, Benzinga reports. The firm currently has a $11.00 target price on the stock.

A number of other research analysts have also weighed in on the company. BTIG Research began coverage on TScan Therapeutics in a research note on Thursday, May 16th. They set a buy rating and a $12.00 price target on the stock. HC Wainwright reaffirmed a buy rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 4th. Finally, Wedbush reaffirmed an outperform rating and issued a $10.00 target price on shares of TScan Therapeutics in a research report on Monday, May 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of Buy and an average price target of $12.00.

TScan Therapeutics Trading Down 1.7 %

Shares of TScan Therapeutics stock traded down $0.10 during trading hours on Monday, reaching $5.90. 8,335 shares of the company’s stock were exchanged, compared to its average volume of 255,165. TScan Therapeutics has a 52-week low of $1.97 and a 52-week high of $9.69. The firm has a market capitalization of $311.87 million, a price-to-earnings ratio of -4.69 and a beta of 0.83. The company has a fifty day moving average of $6.93 and a 200-day moving average of $7.16. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.19.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.07). TScan Therapeutics had a negative return on equity of 61.13% and a negative net margin of 653.50%. The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $3.75 million. Sell-side analysts forecast that TScan Therapeutics will post -1.25 EPS for the current fiscal year.

Institutional Trading of TScan Therapeutics

Several large investors have recently modified their holdings of the business. Tocqueville Asset Management L.P. acquired a new position in TScan Therapeutics in the first quarter worth about $1,685,000. abrdn plc acquired a new position in TScan Therapeutics in the fourth quarter worth about $1,166,000. Bank of New York Mellon Corp acquired a new position in TScan Therapeutics in the second quarter worth about $682,000. Brown Brothers Harriman & Co. acquired a new position in TScan Therapeutics in the second quarter worth about $445,000. Finally, Rhumbline Advisers bought a new position in TScan Therapeutics in the second quarter worth about $274,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.